Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 17:12:680503.
doi: 10.3389/fimmu.2021.680503. eCollection 2021.

Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway

Affiliations
Review

Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway

Julie Constanzo et al. Front Immunol. .

Abstract

In the past decade, radiation therapy (RT) entered the era of personalized medicine, following the striking improvements in radiation delivery and treatment planning optimization, and in the understanding of the cancer response, including the immunological response. The next challenge is to identify the optimal radiation regimen(s) to induce a clinically relevant anti-tumor immunity response. Organs at risks and the tumor microenvironment (e.g. endothelial cells, macrophages and fibroblasts) often limit the radiation regimen effects due to adverse toxicities. Here, we reviewed how RT can modulate the immune response involved in the tumor control and side effects associated with inflammatory processes. Moreover, we discussed the versatile roles of tumor microenvironment components during RT, how the innate immune sensing of RT-induced genotoxicity, through the cGAS-STING pathway, might link the anti-tumor immune response, radiation-induced necrosis and radiation-induced fibrosis, and how a better understanding of the switch between favorable and deleterious events might help to define innovative approaches to increase RT benefits in patients with cancer.

Keywords: STING; bystander immunity; cGAS; inflammation; nucleic acids; radiation; radiotherapy; targeted radionuclide therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Summary of cancer-immune cell interactions after irradiation (EBRT, external beam radiation therapy; TRT, Targeted Radionuclide Therapy) and the involvement of dsDNA,double-stranded DNA; MN, micronucleus; sEVs, small extracellular vesicles; and cGAMP, cyclic GMP–AMP in bystander immunity.
Figure 2
Figure 2
Senescence-associated secretory phenotype (SASP) factors can support or suppress anti-tumor immune responses. On the left, in an immunostimulatory scenario, SASP factors secreted by tumor cells and pericytes drive the recruitment of innate immune cells (macrophages, neutrophils, natural killer (NK) and NK T cells) to mediate the clearance of senescent tumor cells. On the right, in an immunosuppressive scenario, SASP factors secreted mostly by stromal cells recruit immature myeloid cells and myeloid-derived suppressor cells (MDSCs) to dampen the cytotoxic effect of NK cells and CD8+ T lymphocytes. Anti-inflammatory mediators, including IL-6 and IL-8, are also secreted by senescent stromal and tumor cells, further increasing the immunosuppressive environment. Senescent cells are represented by a gray cytoplasm, regardless of their origin. CCL, C–C motif chemokine ligand; CXCL, C–X–C motif chemokine ligand; NK natural killer; NKT, natural killer T lymphocyte.

Similar articles

Cited by

References

    1. Thames HD, Withers HR, Peters LJ, Fletcher GH. Changes in Early and Late Radiation Responses With Altered Dose Fractionation: Implications for Dose-Survival Relationships. Int J Radiat Oncol Biol Phys (1982) 8:219–26. 10.1016/0360-3016(82)90517-X - DOI - PubMed
    1. Thames HD. On the Origin of Dose Fractionation Regimens in Radiotherapy. In: Seminars in Radiation Oncology. WB Saunders; (1992). p. 3–9.
    1. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. . Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer. Int J Radiat Oncol Biol Phys (2014) 88:553–64. 10.1016/j.ijrobp.2013.11.012 - DOI - PMC - PubMed
    1. Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, et al. . The Incidence of Radiation Necrosis Following Stereotactic Radiotherapy for Melanoma Brain Metastases: The Potential Impact of Immunotherapy. Anticancer Drugs (2017) 28:669–75. 10.1097/CAD.0000000000000497 - DOI - PubMed
    1. Yoshii Y. Pathological Review of Late Cerebral Radionecrosis. Brain Tumor Pathol (2008) 25:51–8. 10.1007/s10014-008-0233-9 - DOI - PubMed

Publication types

MeSH terms